CN
Drug Modalities
Technical Solutions
ESG
Newsroom
About Us
Contact Us
CN
CN
Home/Newsroom/News

News 2026-08-31

Porton Newsletter - August 2026 Recap

Others
More
CPHI

News 2026-09-01

Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026

CPHI creates connections and inspires partnerships across the global pharma community, championing innovation at the heart of pharma through in-person and online events that grant access to endless opportunities.

News 2026-08-05

Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization

Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.
Become part of Porton's community to access personalized insights and resources.
Subscribe for the Newsletter
By clicking “Subscribe,” you acknowledge that you have read and agree to our Legal Disclaimer, Terms of Use, and Privacy & Cookie Policy. Porton will use the contact information you provide to communicate with you about our products, services, and other relevant updates. You may unsubscribe at any time. For more information about how we protect your privacy and manage your communication preferences, please review our Privacy & Cookie Policy.
US: (609) 860-1300
CN: (86) 23-8608-3200

ⓒ 2025 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton's community to access personalized insights and resources.
Submit
By clicking “Subscribe,” you acknowledge that you have read and agree to our Legal Disclaimer, Terms of Use, and Privacy & Cookie Policy. Porton will use the contact information you provide to communicate with you about our products, services, and other relevant updates. You may unsubscribe at any time. For more information about how we protect your privacy and manage your communication preferences, please review our Privacy & Cookie Policy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200